CI

At a glance

ClinicalIndex Comparison Record
N/AUnknown· 120 target
Drug / intervention
Crizotinibdrug
Likely dose
Crizotinib 250mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03647111
NCT03647111N/AUnknown
CompareCT.gov

A Real World Study to Evaluate the Efficacy and Safety of First Line Crizotinib in ALK Rearranged Advanced Non Squamous Non-small Cell Lung Cancer

Hunan Province Tumor Hospital·observational·Posted Aug 27, 2018·Updated Dec 27, 2023

In Brief

An observational study evaluating Crizotinib for Non-small Cell Lung Cancer. Targeting 120 participants across 1 site.

Detailed Summary

This study aims to explore the efficacy and safety of Crizotinib as a first-line therapy for advanced non-squamous non-small cell lung cancer with ALK-positive mutations in the real world.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsNon-small Cell Lung Cancer
CountriesChina
Collaborators--

Timeline

N/AUnknownOverdue
201820192020202120222023202420252026
First PostedAug 27, 2018
Enrollment StartJan 1, 2018
Primary CompletionDec 31, 2024
Study CompletionDec 1, 2025
TodayJul 1, 2026
Enrollment to primary: 7 yearsPosted 7.8 years ago

Interventions

Crizotinibdrug

Crizotinib 250mg po bid